ライフサイエンスコーパス: urokinase

1 , where it is cleaved into active plasmin by urokinase.

2 protease-activated receptor-2 (PAR2) and pro-urokinase.

3 y to form covalent inhibitory complexes with urokinase.

4 ecovery was similar to high-dose nontargeted urokinase (500 U/g body weight).

5 We previously generated PA-U2-R200A, a urokinase-activated PA variant with LF-binding subsite I

6 tivator inhibitor 1 (PAI-1), a member of the urokinase activator system that is involved in tumor met

7 plasma membrane cationic current, inhibiting urokinase activity and cell invasion.

8 the urokinase receptor, differences in renal urokinase activity did not account for the increased fib

9 lasminogen in human serum in the presence of urokinase (an activator that converts plasminogen to pla

10 i) the binding of uPAR to its primary ligand urokinase and (ii) the flexible interdomain assembly of

11 stration resulted in increased extracellular urokinase and collagen degradation.

12 had a minor effect on permeability, whereas urokinase and desmoteplase were ineffective.

13 mug/mg hydrogel while the mid-sized protein urokinase and large monoclonal antibody rituximab load a

14 Urokinase and recombinant tissue plasminogen activator a

15 nolysis is considered marginal compared with urokinase and tissue plasminogen activator.

16 Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA

17 chemokine (C-X-C motif) ligand 2, Nidogen1, urokinase, and matrix metalloproteinase 3.

18 ally, the thrombolytic zymogens plasminogen, urokinase, and plasma kallikrein have all been shown to

19 vitro with model proteins salmon calcitonin, urokinase, and rituximab to determine the effects of par

20 o tested release of profibrinolytic enzymes, urokinase, and tissue plasminogen activator (TPA) as a s

21 lated with agonists, and secretion of Hsp90, urokinase, and TPA was measured in the culture supernata

22 matrix metalloproteinase (MMP)-1 and -9, and urokinase- and tissue-type plasminogen activators.

23 have enabled the assembly of a high-affinity urokinase-binding cavity involving all three LU domains

24 prolonged with this high dose of nontargeted urokinase, but not with equally effective targeted scFvS

25 iant human single-chain low molecular weight urokinase construct that can be activated selectively by

26 eptokinase, tissue-plasminogen activator and urokinase have been developed to improve the therapeutic

27 ereby uPAR ligation with its cognate ligand, urokinase, induces a motile phenotype in human lung fibr

28 Furthermore, after thrombolysis with urokinase, LIBS-MB ultrasound imaging allows monitoring

29 ble for the in vivo detection and imaging of urokinase-like plasminogen activator (uPA), which is a k

30 ted through its ability to directly regulate urokinase -mediated activation of plasminogen (Pg).

31 tagonism with clopidogrel, fibrinolysis with urokinase, or DNA digestion with recombinant DNase I all

32 Soluble urokinase plasminogen activation receptor (suPAR) is ris

33 lines, we identified elevated levels of the urokinase plasminogen activation receptor (uPAR, PLAUR)

34 o a >100-fold increase in platelet stores of urokinase plasminogen activator (PLAU/uPA); subsequent p

35 We fused single-chain urokinase plasminogen activator (scuPA) to a small recom

36 -PA, we engineered and expressed a two-chain urokinase plasminogen activator (tcu-PA) cleavage-resist

37 plasminogen activator receptor (u-PAR) binds urokinase plasminogen activator (u-PA) and participates

38 )-9, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA) activities were as

39 Urokinase plasminogen activator (uPA) and its receptor (

40 ing probe to analyze the interaction between urokinase plasminogen activator (uPA) and monoclonal uPA

41 Urokinase plasminogen activator (uPA) and PA inhibitor t

42 We compared the PAR-dependent expression of urokinase plasminogen activator (uPA) and plasminogen ac

43 f certain tumor-associated proteases such as urokinase plasminogen activator (uPA) can be a hallmark

44 Urokinase plasminogen activator (uPA) converts plasminog

45 istance to EGFR TKIs, elevated expression of urokinase plasminogen activator (uPA) drives signaling t

46 escue experiments demonstrate that exogenous urokinase plasminogen activator (uPA) expression can res

47 Two of these antibodies compete against urokinase plasminogen activator (uPA) for uPAR binding,

48 followed by delayed synthesis and release of urokinase plasminogen activator (uPA) from injured brain

49 Urokinase plasminogen activator (uPA) is a biomarker and

50 that platelet (PLT) alpha granule-delivered urokinase plasminogen activator (uPA) is highly effectiv

51 Urokinase plasminogen activator (uPA) is inhibited by PN

52 Here, we show that siRNA targeted to the urokinase plasminogen activator (uPA) promoter induced e

53 The urokinase plasminogen activator (uPA) was the first iden

54 y shown to down-regulate tumor expression of urokinase plasminogen activator (uPA), a protease linked

55 of major players of cell migration, such as urokinase plasminogen activator (uPA), its inhibitor pla

56 CD38B treatment increased endocytosis of the urokinase plasminogen activator (uPA), its receptor (uPA

57 n of both chitosan, targeting acidic pH, and urokinase plasminogen activator (UPA), targeting UPAR.

58 use fibrotic Mfs secrete elevated amounts of urokinase plasminogen activator (uPA), we tested whether

59 been correlated with increased expression of urokinase plasminogen activator (uPA).

60 or FIXa inhibiton based on its homology with urokinase plasminogen activator (uPA).

61 f the primary biochemical target of SerpinB2-urokinase plasminogen activator (uPA).

62 s efficacy is due to the effects of t-PA and urokinase plasminogen activator (uPA).

63 The in vivo effects of APs were tested in urokinase plasminogen activator (uPA)/severe combined im

64 ell culture, and animal models implicate the urokinase plasminogen activator (uPA)/uPA receptor (uPAR

65 removal by healthy cardiocytes and increases urokinase plasminogen activator (uPA)/uPA receptor (uPAR

66 f this study was to evaluate the role of the urokinase plasminogen activator (uPA)/uPA receptor (uPAR

67 roponin I; matrix metalloproteinase (MMP)-2; urokinase plasminogen activator (uPA); urokinase plasmin

68 ly inhibited the active form of the protease urokinase plasminogen activator (uPA, PLAU).

69 odes SerpinB2, an inhibitor of extracellular urokinase plasminogen activator and deletion of DUSP5 ac

70 of angiogenin led to increased activation of urokinase plasminogen activator and generation of active

71 e NF-kappaB pathway, increased expression of urokinase plasminogen activator and matrix metalloprotei

72 Components of the fibrinolytic pathway (urokinase plasminogen activator and plasmin) are elabora

73 EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activato

74 r inhibitor-1 (PAI-1), a potent inhibitor of urokinase plasminogen activator and tissue plasminogen a

75 eam target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial

76 - to 3-fold increase in cerebral tissue-type/urokinase plasminogen activator expression.

77 sminogen and was completely abrogated by the urokinase plasminogen activator inhibitor-1 and serine p

78 or activation by matrix metalloproteases and urokinase plasminogen activator into two of these varian

79 the serine protease thrombin and release the urokinase plasminogen activator loaded into the polymer

80 The soluble cleaved urokinase plasminogen activator receptor (scuPAR) is a c

81 te the potential association between soluble urokinase plasminogen activator receptor (suPAR) and inc

82 tion, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has bee

83 The role of the soluble urokinase plasminogen activator receptor (suPAR) in foca

84 Soluble urokinase plasminogen activator receptor (suPAR) indepen

85 Systemic soluble urokinase plasminogen activator receptor (suPAR) is a ci

86 Soluble urokinase plasminogen activator receptor (suPAR) is a si

87 Soluble urokinase plasminogen activator receptor (suPAR) is an i

88 We have previously observed that soluble urokinase plasminogen activator receptor (suPAR) prevent

89 We investigated whether soluble urokinase plasminogen activator receptor (suPAR), a mark

90 cyte injury) and serum levels of the soluble urokinase plasminogen activator receptor (suPAR), a prop

91 Levels of soluble urokinase plasminogen activator receptor (suPAR), an inf

92 Soluble urokinase plasminogen activator receptor (suPAR), lipopo

93 tein (CRP), procalcitonin (PCT), and soluble urokinase plasminogen activator receptor (suPAR).

94 Urokinase plasminogen activator receptor (u-PAR) binds u

95 Interactions between urokinase plasminogen activator receptor (uPAR) and its

96 Given recent evidence implicating the urokinase plasminogen activator receptor (uPAR) as a "do

97 al studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a the

98 Western blot analysis were used to quantify urokinase plasminogen activator receptor (uPAR) expressi

99 The urokinase plasminogen activator receptor (uPAR) has emer

100 Extensive evidence implicates the urokinase plasminogen activator receptor (uPAR) in tumor

101 Urokinase plasminogen activator receptor (uPAR) is known

102 d 2 mouse models, the wild type (WT) and the urokinase plasminogen activator receptor (uPAR) KO (uPAR

103 Urokinase plasminogen activator receptor (uPAR), a cellu

104 ing strategy: 1) an elevated tumor receptor, urokinase plasminogen activator receptor (UPAR), and 2)

105 s identify the subcellular relocalization of urokinase plasminogen activator receptor (uPAR), LIM and

106 Transcripts of the urokinase plasminogen activator receptor (uPAR), which f

107 ) mutually block each other's binding to the urokinase plasminogen activator receptor (uPAR).

108 ace expression levels of alpha5 integrin and urokinase plasminogen activator receptor (uPAR).

109 P)-2; urokinase plasminogen activator (uPA); urokinase plasminogen activator receptor (uPAR); plasmin

110 morphisms in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) ha

111 Sirt6 also reduces urokinase plasminogen activator receptor expression, whi

112 ives: To study the ability of suPAR (soluble urokinase plasminogen activator receptor), a potential b

113 R1 (tumor necrosis factor receptor 1), UPAR (urokinase plasminogen activator receptor), IGFBP7 (insul

114 in hemangioma-derived stem cells, including urokinase plasminogen activator receptor, interleukin-6,

115 llagen receptors mannose receptor (Mrc1) and urokinase plasminogen activator receptor-associated prot

116 sites via an endocytic mechanism governed by urokinase plasminogen activator receptor-associated prot

117 -50% of endosomes containing proteins of the urokinase plasminogen activator system (uPAS) to relocat

118 l fragment of the receptor binding domain of urokinase plasminogen activator to the surface of functi

119 c proteins matrix metalloproteinase-9, nm23, urokinase plasminogen activator, and cyclooxygenase-2.

120 be induced by exposure to specific ligands (urokinase plasminogen activator, vitronectin), but not v

121 tor-mediated lysis being more efficient than urokinase plasminogen activator-mediated lysis.

122 d administered intravenously to HCV-infected urokinase plasminogen activator-severe combined immunode

123 ease matriptase and subsequent activation of urokinase plasminogen activator.

124 both vascular endothelial growth factor and urokinase plasminogen activator.

125 g triggered by the non-MHC-I-related protein urokinase plasminogen activator.

126 nfluenzae or bound to PE, was accessible for urokinase plasminogen activator.

127 ates proprostasin and cell surface-bound pro-urokinase plasminogen activator.

128 PAI-1 induces the internalization of urokinase plasminogen activator/receptor and integrin al

129 Humanized urokinase plasminogen activator/severe combined immunode

130 rts that it may be an alternative urokinase (urokinase plasminogen activator; uPA) receptor in additi

131 at the same exosite used by both tissue and urokinase plasminogen activators (tPA and uPA).

132 apoptotic cells) and pathologic roles of the urokinase-plasminogen activator/receptor system (leads t

133 Genetic reduction of the uPAR ligand urokinase prevented degradation of fibrin-rich thrombi a

134 olecule ligands in complex with the proteins urokinase, PTP-1B, and Chk-1.

135 Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal mo

136 Recently, serum soluble urokinase receptor (suPAR) has been proposed as a cause

137 Soluble urokinase receptor (suPAR) is a circulatory molecule tha

138 Here we report that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of

139 Serum soluble urokinase receptor (suPAR) levels strongly predict incid

140 The urokinase receptor (u-PAR) which is largely regulated at

141 Hypoxia induces expression of the urokinase receptor (uPAR) and activates uPAR-dependent c

142 s significantly increased levels of cellular urokinase receptor (uPAR) and release increased amounts

143 e that in EGFRvIII-expressing GBM cells, the urokinase receptor (uPAR) functions as a major activator

144 The urokinase receptor (uPAR) is a cell-signaling receptor k

145 The urokinase receptor (uPAR) is a founding member of a smal

146 The urokinase receptor (uPAR) is a glycosylphosphatidylinosi

147 Neither the urokinase receptor (uPAR) nor the low-density lipoprotei

148 The urokinase receptor (uPAR) plays an important role in reg

149 The urokinase receptor (uPAR) promotes metastasis of human m

150 here we report the sequestration behavior of urokinase receptor (uPAR), a glycosylphosphatidylinosito

151 The urokinase receptor (uPAR), expressed on the surface of m

152 We found that uPAR ligation with the urokinase receptor binding domain (amino-terminal fragme

153 The urokinase receptor system is a key regulator of the inte

154 The urokinase receptor urokinase-type plasminogen activator

155 Binding to the urokinase receptor was completely abolished while PAI-1

156 ocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-containing (LYPD)-6B on alpha

157 Although Mrc2 associates with the urokinase receptor, differences in renal urokinase activ

158 hly colocalized on the cell surface with the urokinase receptor, uPAR.

159 Urokinase reduction also ameliorated liver hemorrhage an

160 linked because the high affinity binding of urokinase regulates the binding of uPAR to matrix-embedd

161 as filtered plasminogen may be processed by urokinase, released from renal tubular epithelium, to ge

162 lasminogen activator" OR "streptokinase" OR "urokinase." Search was not limited by year of publicatio

163 e with macrophage-specific overexpression of urokinase (SR-uPA(+/0) mice) and of SR-uPA(+/0) bone mar

164 m corneum from proteolysis via inhibition of urokinase, thereby maintaining the integrity and barrier

165 free mice treated with plasminogen activator urokinase to elevate MDSC have reduced levels of L-selec

166 ed extracellular activity of enzymes such as urokinase, triggering a proteolytic cascade, which culmi

167 ibrinolytic cascade by colocalizing with the urokinase type plasminogen activator and receptor comple

168 or has been developed for rapid detection of urokinase type plasminogen activator receptor (uPAR) - a

169 is the main inhibitor of the tissue type and urokinase type plasminogen activators.

170 imary inhibitor of the tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, has been im

171 We found that neuronal urokinase-type (uPA) protects the synapse from the delet

172 in via two activators: tissue-type (tPA) and urokinase-type (uPA).

173 ostasis after injury following activation by urokinase-type plasminogen activator (u-PA; encoded by t

174 Here, we show that neurons release urokinase-type plasminogen activator (uPA) and astrocyte

175 The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glyco

176 1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix me

177 d the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminog

178 models focus on the ability of uPAR to bind urokinase-type plasminogen activator (uPA) and promote p

179 sly demonstrated that the expression of both urokinase-type plasminogen activator (uPA) and the uPA r

180 tein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA r

181 rpin inhibitor of the plasminogen activators urokinase-type plasminogen activator (uPA) and tissue pl

182 ay regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimatel

183 In addition, urokinase-type plasminogen activator (uPA) and uPA recep

184 al oncospheres upregulated the expression of urokinase-type plasminogen activator (uPA) and/or matrix

185 Mice lacking urokinase-type plasminogen activator (uPA) are highly su

186 s cells produced more of the serine protease urokinase-type plasminogen activator (uPA) as compared w

187 his study identifies the extracellular PAI-1/urokinase-type plasminogen activator (uPA) balance as an

188 Sustained urokinase-type plasminogen activator (uPA) expression is

189 Urokinase-type plasminogen activator (uPA) is a serine p

190 Urokinase-type plasminogen activator (uPA) is a serine p

191 Urokinase-type plasminogen activator (uPA) is a serine p

192 Urokinase-type plasminogen activator (uPA) is expressed

193 Urokinase-type plasminogen activator (uPA) is expressed

194 hypothesized that Mp-specific expression of urokinase-type plasminogen activator (uPA) is sufficient

195 Urokinase-type plasminogen activator (uPA) participates

196 Plasminogen activation catalyzed by urokinase-type plasminogen activator (uPA) plays an impo

197 We hypothesized that urokinase-type plasminogen activator (uPA) promotes musc

198 ree-domain clamp of Argos also resembles the urokinase-type plasminogen activator (uPA) receptor, whi

199 Genetic absence of the urokinase-type plasminogen activator (uPA) reduces arthr

200 Urokinase-type plasminogen activator (uPA) regulates ang

201 ave a significant reduction in expression of urokinase-type plasminogen activator (uPA) relative to t

202 Plasminogen activation by urokinase-type plasminogen activator (uPA) was markedly

203 Interaction of urokinase-type plasminogen activator (uPA) with its rece

204 The trypsin-like serine protease, urokinase-type plasminogen activator (uPA), is central i

205 g factors, such as interleukin (IL)-8, IL-6, urokinase-type plasminogen activator (uPA), or uPA recep

206 Plasminogen can be activated to plasmin by urokinase-type plasminogen activator (uPA), tissue-type

207 as applied to the screening of inhibitors of urokinase-type plasminogen activator (uPA), which is a p

208 ilencing expression of endogenously produced urokinase-type plasminogen activator (uPA), which is nec

209 face receptor capable of not only focalizing urokinase-type plasminogen activator (uPA)-mediated fibr

210 peptide based on consensus cleavage motif of urokinase-type plasminogen activator (uPA).

211 LAM lesions and angiomyolipomas overexpress urokinase-type plasminogen activator (uPA).

212 iring the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metall

213 In addition, we demonstrate that the urokinase-type plasminogen activator (uPA)/uPA receptor

214 Mice deficient in urokinase-type plasminogen activator (uPA-/-) exhibit de

215 ts displayed moderately reduced single-chain urokinase-type plasminogen activator activation.

216 t the effect of L-MIM involves a decrease in urokinase-type plasminogen activator activity.

217 greatly reduced the activity of both tPA and urokinase-type plasminogen activator after HI.

218 d secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in

219 at the translational level by eIF3e included urokinase-type plasminogen activator and apoptotic regul

220 ement with these findings, reduced levels of urokinase-type plasminogen activator and elevated levels

221 ation of collagen IV, and their secretion of urokinase-type plasminogen activator and its receptor.

222 serpin inhibits tPA and, to a lesser extent, urokinase-type plasminogen activator and plasmin.

223 mmune-deficient transgenic mice carrying the urokinase-type plasminogen activator gene driven by the

224 icellular proteolytic cascades by activating urokinase-type plasminogen activator on the cell surface

225 in absence of ADAMTS13, after activation by urokinase-type plasminogen activator or the thrombolytic

226 an effect on the expression/function of the urokinase-type plasminogen activator protease uPA/uPAR s

227 Circulating levels of soluble forms of urokinase-type plasminogen activator receptor (suPAR) ar

228 Recent studies describe soluble urokinase-type plasminogen activator receptor (suPAR) as

229 Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) ha

230 Serum soluble urokinase-type plasminogen activator receptor (suPAR) is

231 ous studies have demonstrated that a soluble urokinase-type plasminogen activator receptor (suPAR) pl

232 Increased plasma level of soluble urokinase-type plasminogen activator receptor (suPAR) wa

233 ulin (beta-2 m), neopterin and suPAR soluble urokinase-type plasminogen activator receptor (suPAR) wa

234 In addition, Pdcd4 knockdown stimulates urokinase-type plasminogen activator receptor (u-PAR) an

235 elial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and

236 Signaling by urokinase-type plasminogen activator receptor (uPAR) can

237 a serine proteinase that upon binding to the urokinase-type plasminogen activator receptor (uPAR) cat

238 The urokinase-type plasminogen activator receptor (uPAR) dri

239 The urokinase-type plasminogen activator receptor (uPAR) has

240 in the mid-1980s, the cell membrane-anchored urokinase-type plasminogen activator receptor (uPAR) has

241 The role of urokinase-type plasminogen activator receptor (uPAR) in

242 explore the potential of PET imaging of the urokinase-type plasminogen activator receptor (uPAR) in

243 The urokinase-type plasminogen activator receptor (uPAR) is

244 The urokinase receptor urokinase-type plasminogen activator receptor (uPAR) is

245 The urokinase-type plasminogen activator receptor (uPAR) is

246 cells, interaction between vitronectin with urokinase-type plasminogen activator receptor (uPAR) on

247 The urokinase-type plasminogen activator receptor (uPAR) pro

248 Expression levels of the urokinase-type plasminogen activator receptor (uPAR) rep

249 We identify the urokinase-type plasminogen activator receptor (uPAR)(11)

250 ule (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a

251 se partitioning, co-immunoprecipitation with urokinase-type plasminogen activator receptor (uPAR), an

252 PET ligand (68)Ga-NOTA-AE105, targeting the urokinase-type plasminogen activator receptor (uPAR), an

253 surface or secreted factors, including CD73, urokinase-type plasminogen activator receptor (uPAR), an

254 g the genes identified, we discovered that a urokinase-type plasminogen activator receptor (uPAR)/int

255 ling pathways downstream of the EGFR and the urokinase-type plasminogen activator receptor (uPAR); ho

256 dinated by many receptors, in particular the urokinase-type plasminogen activator receptor (uPAR, CD8

257 through the interaction with a region of the urokinase-type plasminogen activator receptor (uPAR88-92

258 phosphatidylinositol-linked proteins such as urokinase-type plasminogen activator receptor and endoth

259 ein 7 ([TIMP-2] x [IGFBP7]), and the soluble urokinase-type plasminogen activator receptor are of dia

260 [TIMP-2] x [IGFBP7] and soluble urokinase-type plasminogen activator receptor are promis

261 n of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a varie

262 ive action of cell surface-associated HS and urokinase-type plasminogen activator receptor in the acc

263 Soluble urokinase-type plasminogen activator receptor levels at

264 [IGFBP7] levels over time and serum soluble urokinase-type plasminogen activator receptor levels onc

265 Soluble urokinase-type plasminogen activator receptor performed

266 ncoding the antimicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related pr

267 the rise of nephropathy biomarkers, soluble urokinase-type plasminogen activator receptor, suPAR and

268 The overexpression of urokinase-type plasminogen activator receptors (uPARs) r

269 ty of C4BP, the activation of plasminogen by urokinase-type plasminogen activator to active plasmin w

270 complexes of PAI-1 with low-molecular-weight urokinase-type plasminogen activator to LRP1.

271 Bound to BBA70, plasminogen activated by urokinase-type plasminogen activator was able to degrade

272 ould lead to drug-entrapped vascular grafts: urokinase-type plasminogen activator was entrapped withi

273 rix metalloproteinase-9 and the secretion of urokinase-type plasminogen activator while increasing ti

274 immunodeficient BALB-DeltaRAG/gamma(c) -uPA (urokinase-type plasminogen activator) mice, freshly thaw

275 uPA (urokinase-type plasminogen activator) was related to sys

276 comitant increased expression of its target, urokinase-type plasminogen activator, a known tumor-asso

277 variant failed to activate the single-chain urokinase-type plasminogen activator, and the G221A and

278 the inhibition of interleukin (IL)-6, IL-8, urokinase-type plasminogen activator, and VEGF productio

279 upon activation of PepO-bound plasminogen by urokinase-type plasminogen activator, generated plasmin

280 in vivo efficacy of mAb16-71 in "human liver urokinase-type plasminogen activator, severe combined im

281 by a compensatory increase in expression of urokinase-type plasminogen activator, which activates uP

282 (6) integrin, called alpha(6)p, generated by urokinase-type plasminogen activator-dependent cleavage

283 al (Beas2B) cells decreased basal as well as urokinase-type plasminogen activator-induced PAI-1 expre

284 U1) by costimulation with phorbol esters and urokinase-type plasminogen activator.

285 activities of matrix metalloproteinase-2 and urokinase-type plasminogen activator.

286 iation, and this cleavage may be mediated by urokinase-type plasminogen activator.

287 aprotinin, and the aminoterminal fragment of urokinase-type plasminogen activator.

288 oteins intercellular adhesion molecule-1 and urokinase-type plasminogen activator.

289 th factor 1, leukemia inhibitory factor, and urokinase-type plasminogen activator.

290 owing: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activat

291 for fibrinolysis, increased tissue-type and urokinase-type plasminogen activators, a relatively decr

292 SkzL enhances the activation of [Glu]Pg by urokinase (uPA) approximately 20-fold, to a maximum rate

293 ), able to interact with FPRs and to mediate urokinase (uPA) or fMLF-dependent cell migration.

294 A and oligonucleotides bind tissue-(tPA) and urokinase (uPA)-type plasminogen activators, plasmin, an

295 diction to analyze the binding interfaces of urokinase (uPA):plasminogen activator inhibitor-1 (PAI-1

296 Urokinase (uPA, urinary plasminogen activator) is a seri

297 given reports that it may be an alternative urokinase (urokinase plasminogen activator; uPA) recepto

298 augmented by any of the agonists tested but urokinase was released by IL-1, TNF-alpha, and thrombin

299 IL-1 and TNF-alpha stimulate release of urokinase, which can convert plasminogen to plasmin and

300 o 30 patients, and 7 patients received local urokinase without thrombectomy.